.jpg "Carlo Tascini, MD photo")
First class Professor
University of Udine
Udine, Italy
CURRICULUM VITAE
Carlo Tascini, M.D.
Born in Marsciano (PG), Italy, July 6th, 1963.
Friuli Centrale University Healthcare Company
Head of Infectious Diseases Clinic
Via Pozzuolo 330 – 33100 Udine (Ud)
Tel.: 0432/559355 – 0432/559949
Fax: 0432/559371
Italy
Full name: CARLO TASCINI
Date and place of birth: July 6th, 1963, Marsciano (PG), Italy.
Current Position: Associate Professor Infectious Diseases, Udine University Hospital, 3310, Udine, Italy. Head of the Infectious Diseases Clinic, Udine University Hospital, 33100 Udine, Italy. Head of the school of specialization in Infectious Diseases, Udine University Hospital, 3310 Udine Italy.
Previous Position: Medical Doctor, Head Infectious Diseases Unit, Azienda Ospedaliera dei Colli, Ospedale Cotugno, Italy from 1 july 2016 to 30 november 2019
Working Address: Infectious Diseases Clinic, Udine University Hospital, Via Pozzuolo 330, 33100, Udine Italy
e-mail: c.tascini@gmail.com
MEDICAL EDUCATION
Degree :
-Doctor of Medicine and Surgery (M.D.) at Perugia University (Italy), School of Medicine, March 3th, 1989, with highest honours.
Specializations:
-Infectious Diseases, Perugia University (Italy), School of Medicine, 1993, with highest honours.
-Clinical Microbiology, Perugia University (Italy), School of Medicine,1997, with highest honours.
UNIVERSITY POSITIONS
-First class Professor of infectious diseases University of Udine since November 5h, 2020.
-Head of the school of specialization in Infectious Diseases, Udine University Hospital, 3310 Udine Italy since 5th November 2020.
HOSPITAL POSITION
Assistant, Medical Doctor, Azienda Ospedaliero-Universitaria Pisana
Ospedale di Cisanello - U.O. di Malattie Infettive
Via Paradisa, 2 - 56124 Pisa from 2000 to 2016
Head, Medical Doctor, Prima divisione Malattie Infettive, Via Quagliariello 54, Napoli,8 0131 Italy, from 1th of July 2016 to 30th novembrer 2019
Head of the Infectious Diseases Clinic, Udine University Hospital, 33100 Udine, Italy from 1 december 2019-ongoing
Research experience
Post-doctoral fellowship at Imperial College of Science London from 1996 to 1998 at the laboratory of molecular parassitology..Research project: proteic vector for new anti- M. tubeculosis vaccine.
Research interest:
CVID-19
Pecori D, Della Siega P, Sozio E, Barbano E, Mazzoran L, Zanichelli A, Sbrana F, Federico I, Bassi F, Fabris M, Vendramin I, Sbrojavacca R, Tascini C. Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2: a case description J Investig Allergol Clin Immunol. 2020 Dec 4:0. doi: 10.18176/jiaci.0659.
Catena C, Colussi G, Bulfone L, Da Porto A, Tascini C, Sechi LA. Echocardiographic Comparison of COVID-19 Patients with or without Prior Biochemical Evidence of Cardiac Injury after Recovery. J Am Soc Echocardiogr. 2020 Oct 22:S0894-7317(20)30666-0. doi: 10.1016/j.echo.2020.10.009. Tascini C, Sermann G, Pagotto A, Sozio E, De Carlo C, Giacinta A, Sbrana F, Ripoli A, Castaldo N, Merelli M, Cadeo B, Macor C, De Monte A. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. Intern Emerg Med. 2020 Nov 1:1-7. doi: 10.1007/s11739-020-02542-6.
Gigli GL, Vogrig A, Nilo A, Fabris M, Biasotto A, Curcio F, Miotti V, Tascini C, Valente M. HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome. Neurol Sci. 2020 Dec;41(12):3391-3394. doi: 10.1007/s10072-020-04787-7.
Meini S, Fortini A, Andreini R, Sechi LA, Tascini C. The Paradox of the Low Prevalence of Current Smokers Among Covid-19 Patients Hospitalized in Non-Intensive Care Wards: Results From an Italian Multicenter Case-Control Study. Nicotine Tob Res. 2020 Sep 23:ntaa188. doi: 10.1093/ntr/ntaa188. Online ahead of print.
Cojutti PG, Londero A, Della Siega P, Givone F, Fabris M, Biasizzo J, Tascini C, Pea F. Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. Clin Pharmacokinet. 2020 Oct;59(10):1251-1260. doi: 10.1007/s40262-020-00933-8.
Meini S, Zanichelli A, Sbrojavacca R, Iuri F, Roberts AT, Suffritti C, Tascini C. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?. Front Immunol. 2020 Aug 11;11:2014. doi: 10.3389/fimmu.2020.02014. eCollection 2020.
Meini S, Pagotto A, Longo B, Vendramin I, Pecori D, Tascini C. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. J Clin Med. 2020 Jun 30;9(7):2050. doi: 10.3390/jcm9072050.
Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, De Monte A, Bove T, Curcio F, Bassi F, De Vita S, Tascini C. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care J Clin Virol. 2020 Aug;129:104444. doi: 10.1016/j.jcv.2020.104444. Epub 2020 May 15.
Quartuccio L, Sonaglia A, Pecori D, Peghin M, Fabris M, Tascini C, De Vita S. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6. J Med Virol. 2020 Nov;92(11):2852-2856. doi: 10.1002/jmv.26149. Epub 2020 Jul 22.
Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, Di Marco F, Gori A, Granata G, Mikulska M, Petrosillo N, Richeldi L, Santus P, Tascini C, Vena A, Viale P, Blasi F; Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020 Jul;26(7):880-894. doi: 10.1016/j.cmi.2020.04.031. Epub 2020 Apr 29.
Immunity of crypotococcosis in human.
Menichetti F, Tascini C. Amphotericin versus fluconazole in cryptococcal meningitis. N Engl J Med. 1992; 326: 1568; author reply 1568-9 (IF: 53,298).
Vecchiarelli A, Retini C, Pietrella D, Monari C, Tascini C, Beccari T, Kozel TR. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect Immun. 1995; 63: 2919-23 (IF: 4,165).
Retini C, Vecchiarelli A, Monari C, Tascini C, Bistoni F, Kozel TR. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun. 1996 Aug;64(8):2897-903. (IF: 4,165).
Monari C, Baldelli F, Pietrella D, Retini C, Tascini C, Francisci D, Bistoni F, Vecchiarelli A. Monocyte dysfunction in patients with acquired immunodeficiency syndrome (AIDS) versus Cryptococcus neoformans. J Infect. 1997;35:257-63 (IF: 4,126).
Tascini C, Vecchiarelli A, Preziosi R, Francisci D, Bistoni F, Baldelli F. Granulocyte-macrophage colony-stimulating factor and fluconazole enhance anti-cryptococcal activity of monocytes from AIDS patients. AIDS. 1999 Jan 14;13(1):49-55 (IF: 6,245).
Tascini C, Ferranti S, Gemignani G, Messina F, Menichetti F. Clinical microbiological case: fever and headache in a heavy consumer of eucalyptus extract. Clin Microbiol Infect. 2002;8:437, 445-6 (IF: 4,54).
Epidemiology and therapy of infections caused by MDR gram negative rods
Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother. 1998;42:270-1 (IF: 5,068).
Tascini C, Menichetti F, Bozza S, Fedele M, Preziosi R, Allegrucci M, Del Favero A, Micozzi A, Martino P, Bistoni F. Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center. Clin Microbiol Infect. 1999 Aug;5(8):457-461 (IF: 4,54).
Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect. 2000 Dec;6(12):690-1 (IF: 4,54).
Menichetti F, Tascini C, Ferranti S, Moroni A, Balbone L, Bozza S, Fedele M, Bifarini G, Del Favero A, Bistoni F. Clinical and molecular epidemiology of an outbreak of infusion-related Acinetobacter baumannii bacteremia in an Intensive Care Unit. Infez Med. 2000;1(8):24-29.
Tascini C, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, Menichetti F. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother. 2004;16:282-7 (IF: 1,084).
Biancofiore G, Tascini C, Bisà M, Gemignani G, Bindi ML, Leonildi A, Giannotti G, Menichetti F. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol. 2007 Mar;73(3):181-5. Epub 2006 Dec 12(IF: 2,656).
Sbrana F, Malacarne P, Bassetti M, Tascini C, Vegnuti L, Della Siega P, Ripoli A, Ansaldi F, Menichetti F. Risk factors for ventilator associated pneumonia due to carbapenemase-producing klebsiella pneumoniae in mechanically ventilated patients with tracheal and rectal colonization. Minerva Anestesiol [Internet]. 2016;82(6):635-40 (IF: 1.78).
Di Pilato V, Arena F, Tascini C, Cannatelli A, Henrici De Angelis L, Fortunato S, Giani T, Menichetti F, Rossolini GM. Mcr-1.2, a new mcr variant carried on a transferable plasmid from a colistin-resistant KPC carbapenemase-producing klebsiella pneumoniae strain of sequence type 512. Antimicrob Agents Chemother [Internet]. 2016;60(9):5612-5 (IF: 4.476).
Lambelet P, Tascini C, Fortunato S, Stefanelli A, Simonetti F, Vettori C, Leonildi A, Menichetti F. Oral gentamicin therapy for KPC-producing Klebsiella pneumoniae gut colonization in haematoloigc patients: a single center experience. New Microbiol. 2017;40:161-164(IF: 1.629).
Meini S, Laureano R, Tascini C, Arena F, Fani L, Frullini A, Passaleva MT, Roberts AT, Mannini D, Sbrana F, Ripoli A, Rossolini GM. Clinical outcome of elderly patients with bloodstream infections due to ESBL-producing Enterobacteriaceae in an italian Internal Medicine Word. Eur J Intern Med. 2017 Oct 28. pii: S0953-6205(17)30422-3. doi: 10.1016/j.ejim.2017.10.014. [Epub ahead of print] (IF: 2.960).
Udine, 17 September 2025
Prof. Carlo Tascini
Disclosure(s): A. Menarini Industrie Farmaceutiche Riunite S.R.L.: Honoraria; AdvanzPharma: Advisor/Consultant, Honoraria; Angelini: Honoraria; Beckman-Coulter: Honoraria; Biotest: Honoraria; DiaSorin: Honoraria; Gilead: Honoraria; Hikma: Advisor/Consultant, Honoraria; INFECTOPHARM: Honoraria; Merck, Sharpe & Dohme: Advisor/Consultant, Honoraria; Pfizer, Inc.: Advisor/Consultant, Honoraria; Thermo Fisher, Inc.: Advisor/Consultant, Honoraria; Viatris: Advisor/Consultant, Honoraria
Monday, October 20, 2025
1:45 PM - 3:00 PM US ET
144 - Should Vancomycin Be Replaced in the MRSA Guidelines? - Pro
Monday, October 20, 2025
2:03 PM - 2:21 PM US ET